YS-ON-001 was granted orphan drug designation by FDA for the treatment of hepatocellular carcinoma. YS-ON-001 is a promising biological product with immunomodulating effects, such as induction of anti-tumor cytokines, activation of NK cells, regulation of macrophage polarization, and suppression of regulatory T cells. YS-ON-001 is a clinical stage biological product based on proprietary immunomodulating cell...
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
